See the 18-slide pitch deck a genetics startup used to raise $100 million and explore the 'dark side' of the genome

CAMP4
arc beats above · slides in the middle · loops below · scroll → 1 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

3
coverage by narrative range · generated from this deck JSON

Slide inventory

18
every slide · same image gating as the playbook
01
Slide 1
The title uses a pun on 'DNA' to reference the company's focus on RNA therapeutics.front_matter
02
transition
03
The slide uses a four-column layout to explain the technology and a footer banner for investor logos.present_solution
04
Uses a biological mechanism diagram to explain the problem (haploinsufficiency) and a roadmap-style matrix for the business strategy.frame_problem
Open slide detailBeat · Problem (Identify pain)
05
The slide uses a checkmark system to indicate successful PoC and text labels for planned studies.show_traction
06
The slide uses a stylized 'A' logo with a circular arrangement of dots, likely representing the company's brand identity.other
07
transition
08
Scientific illustration of molecular biology mechanisms.establish_context
09
The slide uses a process flow diagram to illustrate the company's proprietary platform.present_solution
10
The slide uses a Gantt-style visualization to show progress across discovery, preclinical, and IND-enabling stages.plan_implementation
11
transition
12
Includes a scientific diagram of SCN1A protein structure and mutation sites.frame_problem
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
13
The diagram illustrates the genetic mechanism (ASOs targeting NAT to release SCN1A). The chart shows a clear dose-response relationship.present_solution
Open slide detailBeat · Solution (Provide relief)Loop · Cost Of Inaction
14
Data source: Hsiao et al, eBiomedicine, 2016show_traction
Open slide detailBeat · Solution (Provide relief)Loop · Cost Of Inaction
15
N=3, dose day 1,14; sacrifice day 21. Safety data indicates >25X therapeutic margin.show_traction
Open slide detailBeat · Solution (Provide relief)Loop · Cost Of Inaction
16
The slide uses a circular diagram to represent 'Dravet Unmet Needs' surrounded by three key pain points.size_opportunity
Open slide detailBeat · Solution (Provide relief)Loop · Cost Of Inaction
17
transition
Open slide detailBeat · Solution (Provide relief)
18
The slide uses a central pyramid diagram to represent the platform's core capabilities and expansion strategy.present_solution
Open slide detailBeat · Solution (Provide relief)